Učitavanje...

Discovery of a Potent Dual ALK and EGFR T790M Inhibitor

The mutational activations of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) are validated oncogenic events and the targets of approved drugs to treat non-small cell lung cancer (NSCLC). Here we report highly potent dual small molecule inhibitors of both ALK and EGFR, p...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Med Chem
Glavni autori: Jang, Jaebong, Son, Jung Beom, To, Ciric, Bahcall, Magda, Kim, So Young, Kang, Seock Yong, Mushajiang, Mierzhati, Lee, Younho, Jänne, Pasi A., Choi, Hwan Geun, Gray, Nathanael S.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800871/
https://ncbi.nlm.nih.gov/pubmed/28528303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejmech.2017.04.079
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!